EU-Funded Project Aims to Revolutionize Tissue Regeneration Through Innovative Bioprinting Platform
Teltow, 05. February 2025 – The European Union has recently launched the micro2MACRO (m2M) project, a groundbreaking initiative aimed at advancing tissue regeneration through the use of a cutting-edge bioprinting platform.
The project, which began in December 2024, focuses on the precise patterning of cell aggregates and microtissues into customizable, stable grafts that can effectively remodel into functional tissues after implantation. With a strong emphasis on scalability and personalization, m2M brings together top academic institutions, research centers, and companies to develop state-of-the-art grafts for tissue repair.
“We are honored to be a partner in the m2M project and are confident in its potential to significantly advance the development of therapies for tissue regeneration. We are excited to contribute our 30 years of experience in the field of regenerative medicine, as well as our regulatory expertise as the holder of an EU-approved cell-based therapy for cartilage repair,” stated Dr. Giulietta Roël, Executive Director of CO.DON GmbH.
In addition to technical development, the m2M project will also promote knowledge exchange and workshops to enhance the skills of researchers and healthcare professionals across Europe. Interested individuals can follow the project’s progress on their LinkedIn page.
More information about the research project and its funding can be found on their website.
CO.DON GmbH is a company that specializes in the development, production, and distribution of autologous cell therapies for the minimally invasive repair of cartilage defects. Their marketed product is a cell therapy treatment for cartilage damage in the knee joint, using the patient’s own cartilage cells. With over 20,000 patients already treated, CO.DON’s method has proven to be successful. In January 2023, CO.DON GmbH was acquired by ReLive Biotechnologies, a global company headquartered in the US.
Dr. Ying Zhou serves as the Managing Director of CO.DON.
For more information, please visit www.codon.de and www.relivebio.com.
Contact:
Matthias Meißner
Director Corporate Communications
T: +49 (0)341 99190 330
E: pr@codon.de
Distributed by https://pressat.co.uk/
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.